Background: Ewing sarcoma (ES) is currently staged using Radiography, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI) and skeletal scintigraphy (bone scan).
involving the Ewing sarcoma RNA (ribonucleic acid) binding protein 1 gene (EWSR1 gene; Ewing sarcoma breakpoint region 1) is mandatory for diagnosis . Ewing sarcoma constituted 1.6% of all cancers in Norwegian children below 15 years of age in the period 1985-2015 (Nasjonalt kvalitetsregister for barnekreft, Kreftregisteret, 2015) . Median age at presentation was 14 years (Helsedirektoratet Avdeling sykehustjenester Oslo Norway, 2015) . Patients with local disease have a fiveyear survival rate of 65-75%, which has improved over the last decades (Group EESNW, 2014; Gaspar et al., 2015) . 25% of the patients will have detectable metastases at presentation . With the presence of pulmonary metastases fiveyear survival is reduced to 30% while patients with both pulmonary and skeletal metastases have a five-year survival rate of less than 10% (Helsedirektoratet Avdeling sykehustjenester Oslo Norway, 2015) . In addition to the presence of metastases, the most important negative prognostic factors are: large tumour volume, high serum lactate dehydrogenase (LDH) levels, tumour in axial skeleton and age > 15 years (Group EESNW, 2014) . Correct staging of the disease is paramount to correct treatment allocation. The Norwegian National Guidelines (Helsedirektoratet Avdeling sykehustjenester Oslo Norway, 2015) are largely based on protocols from the Italian and Scandinavian Sarcoma Groups (ISG/SSG) (Italian Sarcoma Group (Bologna Italy), Scandinavian Sarcoma Group (Oncologic Center Lund Sweden), 1999a; Italian Sarcoma Group (Bologna Italy), Scandinavian Sarcoma Group (Oncologic Center Lund Sweden), 1999b) and recommend a combination of some, or all, of the following imaging modalities for staging of Ewing Sarcoma: Radiography, ultrasound, CT, MRI, skeletal scintigraphy with 99m Tc-labelled bisphosphonates (bone scan) and 18 F-FDG PET-CT.
Radiography, CT and MRI of tumour site, affected limb and adjacent joints, and skeletal scintigraphy are considered mandatory examinations while ultrasound of tumour site, angiography of affected limb, abdominal CT (in patients with lesions not involving the abdomen) and 18 F-FDG PET-CT are optional.
The use of 18 F-FDG PET-CT in staging, restaging and assessment of therapy response in patients with Ewing sarcoma is increasing worldwide even though the method at present is not considered a standard examination in the diagnostic work-up of these patients (Group EESNW, 2014; Biermann et al., 2017) . PET imaging with 18 F-FDG depicts upregulated glucose metabolism in cancer cells in
Ewing sarcoma as well as in other solid tumours. Maximum standard uptake value (SUVmax) in Ewing sarcoma tumours is highly variable ranging from 3 to 21 (Charest et al., 2009 ) and 2-11 (Quartuccio et al., 2015) in different series. Highly aggressive, fast growing tumours (higher -grade tumours) usually demonstrate more intense 18 F-FDG uptake than lower grade tumours. This can be used to target biopsy to the most metabolic active area of a given tumour and to characterise indeterminate lesions (Lakkaraju et al., 2010) . In a recently published study, Palmerini et al., found that SUV max of primary tumours predicted outcome (event free survival) in patients with Ewing sarcoma and they suggest that it may be used as a prognostic factor along with other prognostic factors such as tumour size, localisation of primary tumour and patient age (Palmerini et al., 2017) . Dedicated paediatric PET-CT protocols which include individual weight-based activities of 18 F-FDG (Lassmann & Treves, 2014) and low dose CT, are established at all the PET sites in Norway. Despite using child specific PET-CT protocols, patients will receive an effective radiation dose of 8 mSv to 13 mSv from a single investigation (Alessio et al., 2009) , the CT component contributing to 40%. The aims of this national population-based study were to evaluate the potential benefit of 18 F-FDG PET-CT in staging of patients with Ewing sarcoma, and to examine to which degree information from 18 F-FDG PET-CT affected the treatment decisions. We also estimated the radiation doses received by the patients during diagnostic work-up including the contribution from 18 F-FDG PET-CT. Group, 1979) . Sixty-one patients were below 30 years of age. Nineteen patients had a pre therapeutic 18 F-FDG PET-CT and minimum follow-up time of 12 months and were included in the study. Depending on the extent of disease at diagnosis, the patients in our study were allocated to one of two Italian-Norwegian joint study protocols: ISG/SSG III and ISG/SSG IV (Italian Sarcoma Group (Bologna Italy), Scandinavian Sarcoma Group (Oncologic Center Lund Sweden), 1999a; Italian Sarcoma Group (Bologna Italy), Scandinavian Sarcoma Group (Oncologic Center Lund Sweden), 1999b), or to Euro Ewing 2008 (Group EES, 2010) . Medical records, pathology results and all pre therapeutic imaging reports were collected for each patient. All 18 F-FDG PET-CT studies have been performed at PET-CT scanners located at the Oslo University Hospital or Haukeland University Hospital.
Material and methods

Patient population
Imaging
Imaging reports from pre therapeutic 18 F-FDG PET-CT examinations were compared with those from conventional imaging (ultrasound, Radiography, CT, MRI, skeletal scintigraphy). Since many patients are examined for several weeks until the diagnosis of Ewing sarcoma is finally proven by biopsy, we included all reports from imaging performed four months prior to, and 1 month after, the date of the pre therapeutic 18 F -FDG PET-CT study. The skeletal scintigraphies consisted of planar images from skull to feet at one or several time points after injection, supplemented with Single Photon Emission Tomography CT (SPECT-CT) in two patients. The 18 F-FDG PET-CT examinations were performed from skull to feet with arms above the head approximately 60 min after intravenous administration of 18 F-FDG. The information from all pre therapeutic imaging was compared with information from subsequent imaging, histology examinations of operation specimens and medical reports during a minimum of 12 months of follow-up.
Dose estimations
Conventional imaging (ultrasound, Radiography, CT, MRI, skeletal scintigraphy) were performed at various sites: local hospitals, regional hospitals, and university hospitals in Norway. All CT examinations (type and number) and skeletal scintigraphies (number) were recorded for each patient. Effective radiation doses from standardized CT examination (Siemens, 2006) were estimated using the software CT-Expo (Stamm & Nagel, 2002) . The patient data were matched to mathematical phantoms corresponding to an average new-born, 6-year-old, or adult. Patient weight was approximated by percentile growth curves for different age categories (Júliusson et al., 2009 ) and adapted to the available phantom sizes. For the nuclear medicine imaging procedures, maximum injected activity followed the European Association of Nuclear Medicine (EANM) paediatric dosage card recommendation (Lassmann & Treves, 2014) . A nuclear medicine radiation dose tool (SNMI) based on the bio kinetic model of radiopharmaceutical distribution issued by the International Commission on Radiological Protection (ICRP 106) (ICRP, 2008) , was applied and effective doses estimated for mathematical phantoms corresponding to an average 1-, 5-, 10-, 15-year-old, or adult.
Compliance with ethical standards
Informed consent for registration in the National Sarcoma Register at Oslo University Hospital was obtained for all study patients. The study was approved as a qualitycontrol study by the Regional Medical Ethics Committee of Western Norway and the local Data Protection officer.
Results
Patient characteristics
Nineteen patients met the inclusion criteria of this study (Fig. 1) . Patient characteristics including stage of disease at diagnosis, amount of pre therapeutic conventional imaging and SUV max of primary tumour are listed in Table 1 . Mean age of the patients was 16 years (range 5-26 years). Mean follow-up was 33 months (range 5-62 months; median 27 months). One patient died 5 months after diagnosis. The primary tumours were located in the skull (n = 1), upper extremity (n = 1), rib (n = 5), spine (n = 1), pelvis (n = 4) or lower extremity (n = 3). Three patients had Ewing sarcoma originating from soft tissue. In one patient with multiple skeletal metastases at diagnosis, the primary tumour site remained unknown. Eight patients in our cohort had metastases at diagnosis. None of the remaining 11 patients developed metastases during follow-up. At the end of the study period, December 31st 2013, four of 19 patients had died of the disease and one patient with metastases had progression of disease. The remaining 14 patients were alive and considered free of disease.
Imaging
There was full concordance between conventional imaging modalities and 18 F-FDG PET-CT regarding localization of primary tumour in 16 patients (84%) and regarding metastases in 11 patients (58%), respectively. Discrepancies in localization of primary tumour could not be evaluated in two patients due to partly removal of tumour before initial 18 F-FDG PET-CT in one patient, and undetectable primary tumour site in the other patient. Conventional imaging modalities and 18 F-FDG PET-CT differed both regarding primary tumour site and metastases in one patient (tumour and skeletal metastases did not have increased FDG uptake) and regarding metastases in another seven patients. Four 18 F-FDG PET-CT studies (21%) detected true FDG positive metastases not found by conventional imaging, one study was false negative due to lack of FDG uptake and three studies showed false FDG positive lesions. The added true FDG positive lesions found by the 18 F-FDG PET-CT examinations in four patients did not lead to any changes in the already planned treatment based on information from conventional imaging as they all had extensive metastatic disease.
Dose estimations
The pre therapeutic imaging consisted of 1-3 CT examinations (mean 2), 0-1 skeletal scintigraphy (mean 1) and one 18 F-FDG PET-CT examination per patient.
Estimated mean effective dose from CT was: 7 mSv (range 2-16), skeletal scintigraphy: 3 mSv (0-5), and 18 F-FDG PET-CT: 5 mSv (4-6), respectively. Total estimated effective dose from all pre therapeutic imaging, was 15 mSv (8-24). Estimated dose contribution from CT, skeletal scintigraphy and 18 F-FDG PET-CT for each of the 19 patients are shown in Fig. 2 .
Discussion
In this population-based national cohort of children and young adults diagnosed with Ewing sarcoma during the period 2005-2012, we found that 18 F-FDG PET-CT detected more metastases than conventional imaging in 21% of the patients. This did not; however, upstage any of the patients as they all had extensive metastatic disease shown by conventional imaging and no changes in planned treatment was made. In one patient the 18 F-FDG PET-CT study was false negative. 18 F-FDG PET-CT showed false positive lesions in three patients. The estimated cumulative mean effective radiation dose (Quartuccio et al., 2015; Fuglo et al., 2012) . In a study of 89 patients with high-grade bone-and soft tissue sarcomas (11 with Ewing sarcoma) by Fuglø et al., 18 F-FDG PET-CT had a high sensitivity of 95%, and specificity of 96% for detecting distant metastases (Fuglo et al., 2012) . In a study of 44 patients with Ewing sarcoma, Quartuccio et al. found that 18 F-FDG PET-CT had superior performance on follow-up than for initial staging (accuracy 85% versus 69%) (Quartuccio et al., 2015) . 18 F-FDG PET-CT detected more metastatic lesions in nine patients (21%) and characterized suspected lesions more accurately in twelve patients (27%). Their analyses showed that 18 F-FDG PET-CT performed similar to MRI in detecting skeletal metastases. In a retrospective study of 53 patients with skeletal Ewing sarcoma, Sharma et al. found that 18 F-FDG PET-CT had a high accuracy (92%) for detecting recurrence in patients with primary Ewing sarcoma (Sharma et al., 2013) . However, the authors admitted that lack of histopathological confirmation of all metastases and lack of data from conventional imaging might have led to a falsely high sensitivity for 18 F-FDG PET-CT.
In one patient with multiple skeletal metastases, the 18 F-FDG PET-CT study was found to be false negative. The skeletal metastases were easily detectable on whole body MRI while no increased uptake of radioactive tracer in the skeleton were seen in the 18 F-FDG PET-CT study or the skeletal scintigraphy images. Without performing whole body MRI in this patient, the skeletal metastases might have been missed. In three patients with local disease the 18 F-FDG PET-CT studies showed false positive findings. In one patient 18 F-FDG PET-CT showed a focal FDG uptake in muscle that subsequent biopsy proved to be benign. In two other patients 18 F-FDG PET-CT showed on hydroxyapatite crystals in areas of bone with increased osteoblastic activity.
Osteosclerotic lesions with high ostoblastic activity are therefore more easily detected in skeletal scintigraphy than pure osteolytic lesions. Ulaner et al. (Ulaner et al., 2014) did a retrospective review of pre therapeutic MDP skeletal scintigraphy and 18 F-FDG PET-CT examination in 60 patients with Ewing sarcoma (12 had skeletal metastases). They found that the MDP skeletal scintigraphy did not add any new information when the primary tumour was osteolytic. When the primary tumour was osteosclerotic however, the MDP skeletal scintigraphy was more sensitive than 18 F-FDG PET-CT in detecting osseous metastases. In a retrospective study of 91 patients with Ewing sarcoma with pre therapeutic skeletal scintigraphy and 18 F-FDG PET (not combined with CT), Newman et al., found that 18 F-FDG PET was slightly superior to skeletal scintigraphy in screening for skeletal metastases (Newman et al., 2013) . The skeletal scintigraphies had however, a higher sensitivity for detection of skeletal lesions in the skull due to increased FDG uptake in brain obscuring nearby focal FDG uptake in the skull in the 18 F-FDG PET-CT images. We observed full concordance regarding skeletal lesions between skeletal scintigraphy and 18 F-FDG PET-CT in the fourteen patients having both examinations.
One of the strengths of our study is that we have only included patients with histopathological proven tumours belonging to the Ewing sarcoma family of tumours (Murphey et al., 2013) . Other studies evaluating 18 F-FDG PET-CT and Ewing sarcoma have a mixed population of patients with other bone sarcomas, soft tissue sarcomas and Ewing sarcoma (Quartuccio et al., 2015; Fuglo et al., 2012; Sharma et al., 2013) . Our study is a population-based national retrospective study of all patients below 30 years of age diagnosed with Ewing sarcoma between January 1st 2005 and December 31st 2012 and all patients have been treated according to the national guidelines of Ewing sarcoma (Helsedirektoratet Avdeling sykehustjenester Oslo Norway, 2015). We have a very comprehensive set of comparable conventional imaging on all the patients and we have complete medical data including radiological, nuclear medicine and pathology reports on all patients, for a minimum follow-up of 12 months. Quartuccio et al. (Quartuccio et al., 2015) found changes in management that could be linked to the added information from the 18 F-FDG PET-CT studies in nine of the 64 patients (14%). As discussed in their study it is hard to evaluate the effects of imaging findings on patient management in a retrospective study since treatment decisions are taken by physicians influenced by many additional factors other than imaging findings, and the treatment decision is not always well documented. In our patient cohort, pre therapeutic 18 F-FDG PET-CT gave additional information compared to conventional imaging in four of the patients in our study (4 of 19). The added information had, however, no impact on the planned treatment in any of these patients as they all had extensive metastatic disease at time of diagnosis. The increased amount of radiation from 18 F-FDG PET-CT of 33% of the total radiation dose from all staging examinations seems justifiable regarding the usefulness of the added information. The present study has some limitations. Ewing sarcoma is a rare disease and in order to collect enough patients retrospective studies are usually applied. Our patient cohort is too small to perform any calculations regarding accuracy of the method 18 F-FDG PET-CT in staging of Ewing sarcoma patients. However, the study provides an insight of how useful the method has been in evaluating disease burden in the 19 patients in our cohort during the period 2005 to 2012. As the study is a retrospective qualitycontrol study, we did not have consent to re-evaluate the images. We have compared the radiological and nuclear medicine reports given by the various radiologists and nuclear medicine specialists at the time of diagnosis. The reporting specialists not only base their reports on the present examinations but also take into account all available examinations and are not "blinded" to the results from prior imaging of the patient. Our study describe the "real life" scenario where all information from existing studies are considered together when staging a patient and not a "study design" scenario where the 18 F-FDG PET-CT studies are read by specialists "blinded" from the results from conventional imaging. When estimating the total effective radiation dose the patients receives during staging, we chose to leave out all radiation doses from planar radiography. In a previous study we have conducted on radiation doses in patients with Ewing sarcoma, we found that the estimated effective doses of all the planar radiography examinations during staging and treatment contributed to only 7% of the total estimated radiation doses from all nuclear and radiological imaging (Johnsen et al., 2016) . We estimate that the planar radiography examinations performed during staging contributed to less than 7% and therefore chose to omit these examinations in our estimation.
Conclusion
Pre therapeutic 18 F-FDG PET-CT of patients with Ewing sarcoma improves detection of metastases compared to conventional imaging. False FDG positive lesions are quite common and supplementary imaging or biopsies are often necessary. Radiation dose from the 18 F-FDG PET-CT examination amount to 1/3 of the total estimated cumulative mean radiation dose received by the patients from other imaging modalities during staging of their disease.
